Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis;Inhaliertes Prostazyklin und Iloprost bei schwerer sekundarer pulmonaler Hypertonie durch Lungenfibrose

Pneumologie

Volumn 54, Issue 3, 2000, Pages 133-142

  Olschewski, Horst ^a   Ardeschir Ghofrani, H ^a   Walmrath, D ^a   Schermuly, R ^a   Temmesfeld Wollbruck B ^a   Grimminger, F ^a   Seeger, W ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; FEMALE; HEART FAILURE; HUMAN; LUNG ARTERY PRESSURE; LUNG FIBROSIS; LUNG GAS EXCHANGE; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME; VASODILATATION;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; EPOPROSTENOL; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NITRIC OXIDE; OXYGEN INHALATION THERAPY; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; VASODILATOR AGENTS;

EID: 0034007136     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9076     Document Type: Article

References (22)

1. 1 Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khonstanteen I, Piper S, Ramsden M, Rosenbach TO, Sukenik S, Wilkinson S, Keystone EC. Mortality in systemic sclerosis (scleroderma). QJ Med 1992; 82: 139-148
2. 2 Barst RJ, Rubin LJ, Goon MC MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continous intravenous prostacyclin. Ann Int Med 1994; 121: 409-415
3. 3 Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301
4. 4 Rubin LJ. Primary Pulmonary Hypertension. N Engl J Med 1997; 336: 111-117
5. 5 Agusti AGN, Rodriguez-Roisin R. Effect of pulmonary hypertension on gas exchange. Eur Respir J 1993; 6: 1371-1377
6. 6 Kinsella JP, Neish SR, Shaffer E, Abman SH. Long-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340: 819-820
7. 7 Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340: 818-819
8. 8 The neonatal inhaled nitric oxide study group. Inhaled nitric oxide in full-term and nearly full-term with hypoxic respiratory failure. N Engl J Med 1997; 336: 597-604
9. 9 Roberts JD, Fineman JR, Zapol WM, Morin III FC, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Briegel J, Welte M, Peter K. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336: 605-610
10. 10 Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-405
11. 11 Williamson DJ, Hayward C, Rogers P, Wallman LL, Sturgess AD, Penny R, Macdonald PS. Acute Hemodynamic Responses to inhaled nitric oxide in Patients With Limited Scleroderma and Isolated Pulmonary Hypertension. Circulation 1996; 94: 477-482
12. 12 Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993; 342: 961-962
13. 13 Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 991-996
14. 2 aerosol versus nitric oxide for selective pulmonary vasodilatation in hypoxic pulmonary vasoconstriction. Eur Surg Res 1993; 25: 329-340
15. 15 Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 1995; 151: 724-730
16. 16 Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M, Briegel J, Welte M, Peter K. Inhaled prostacyclin versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 1671-1677
17. 17 Olschweski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seeger W. Aerosolized prostacyclin and Iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824
18. 18 Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 384-389
19. 19 Warren JB, Higenbottam T. Caution with the use of inhaled NO. Lancet 1996; 348: 629
20. 20 Wagner PD, Saltzman HA, West JB. Measurement of continuous distributions of ventilation-perfusion ratios: theory. J Appl Physiol 1974; 36: 588-599
21. 21 Miller O, Tang S, Keech A, Celermajer D. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346: 51-52
22. 22 Pepke-Zaba J, Higenbottam TW, Ding-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-1174